Esoteric Testing Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2024-2030)

Esoteric Testing Market Trends & Drivers

• Worldwide, chronic diseases, including diabetes, heart disease, and cancer, are becoming increasingly common. Similarly, the prevalence of infectious diseases is rising at an alarming rate, especially of dengue, hepatitis B and C, HIV, malaria, and tuberculosis.
• Additionally, the knowledge of the advantages of using esoteric testing for the early and accurate detection of certain disorders is growing, especially of the fact that the advancing technology in these tests provides quicker results with higher efficacy, sensitivity, and detection limits. Specifically, the rising usage of esoteric DNA sequencing, NGS, and whole-genome sequencing for the early diagnosis of cancer and in precision medicine is pushing the growth.
• According to the WHO, non-communicable diseases kill 41 million people every year globally. In 2021, 247 million cases of malaria were estimated worldwide, and the number of deaths stood at 619 000.
• Moreover, a total of 1.6 million people died from tuberculosis in 2021, including 187,000 people with HIV. Worldwide, TB is the 13th-leading cause of death and the second-leading infectious killer.
• The market is primarily driven by an increase in the demand for ELISA and RT-PCR tests as a result of the rise in the prevalence of chronic infections and rare genetic illnesses. There is also a significant rise in the funding from public and commercial institutions for diagnostic services and technological advances in esoteric testing.
• Additionally, the combination of these technologies, which detects nucleic acid instead of protein, is witnessing rapid adoption due to its shorter analytical time. Its high specificity and sensitivity, together with its semiquantitative ability, give it a huge potential to serve as a powerful detection tool in various industries, such as medical, veterinary, and agriculture.
• With the recent advances in PCR-ELISA, the assay has become more widely recognized for its fast and sensitive detection, which has improved the overall diagnostic quality and quickened up the process.

Esoteric Testing Market Analysis

Infectious Disease Testing Category Dominates Market

Based on test type, the infectious disease testing category accounted for the largest share, of more than 24%, in the market, due to the rising demand for technically advanced molecular diagnosis methods, itself on account of the increasing burden of infectious diseases. Additionally, the improvements in the healthcare infrastructure of developing countries have led to the large share of the category.

The genetic testing category is expected to grow with the highest CAGR, due to the advancing genetic testing technologies, growing count of genetic disorder patients, increasing awareness of genetic testing for cancer screening and prenatal screening, and government support for fast and accurate genetic diagnoses.

Furthermore, oncology testing is expected to show significant growth in the esoteric testing market during the forecast period. The growing significance of early cancer identification and treatment will favorably affect the market expansion in this sector. Cancer is ranked the second-biggest cause of death. Globally, nearly 10 million new cases of cancer were reported in 2022. Lung, breast, and prostate cancers are the three most-prevalent types of cancer. Therefore, the rising R&D spending in the field of oncology would increase the usage of enhanced tests.

Chemiluminescence Immunoassay (CLIA) Accounted for Largest Share

Based on technology, the market is categorized into chemiluminescence immunoassay, ELISA, mass spectrometry, RT-PCR, DNA sequencing, flow cytometry, and others. Among these, CLIA accounted for the largest revenue share for esoteric testing market, and it is further expected to maintain its dominance in the future. This is owing to his high performance, in terms of precision, efficacy of diagnosis, and ability to detect analytes present in minute quantities. Other than these reasons, it is predicted that the increase in the research and development efforts related to the diagnosis of autoimmune disorders, where CLIA is heavily utilized to evaluate the symptoms, will accelerate the category's growth in the future.

However, the DNA sequencing category is expected to witness the fastest growth during the forecast period, owing to the rising prevalence of infectious diseases, including hepatitis, dengue, and AIDS, along with neurological disorders and cancer. Along with this, the booming geriatric population and the rising demand for affordable diagnostic testing services will propel the advance of this category.

Moreover, the usage of ELISA will grow significantly during the prediction time frame. One of the main factors influencing the demand for this test is its ability to recognize numerous disease antigens. For instance, indirect ELISA-based assays are widely used to test the blood or saliva for HIV. Thus, the growing use of ELISA to identify diverse disease-causing agents creates a sizable opportunity for the market participants to make investments for the creation of novel ELISA kits.

Geographical Analysis

Geographically, North America held the largest share, of around 36%, in 2022, and it is expected to grow at a robust CAGR during the review period, due to the high per capita income and healthcare expenditure, vast population of the elderly and chronic disease patients, and the presence of leading companies in the region. Moreover, the increase in the number of diagnostic tests and technological advancements in esoteric tests are the other key factors aiding the growth of the market in the region.

Furthermore, Canada is showing significant growth in this market due to its advancing healthcare infrastructure, rising number of government initiatives for making diagnostic services accessible and affordable, surging demand for ELISA and RT-PCR tests, and the presence of key players providing the associated assay kits, reagents, and testing equipment.

Specifically, companies are launching advanced products in the region for the early detection of cancer. For instance, Myriad Genetics Inc. introduced the EndoPredict test for patients with ER+ HER2-early-stage breast cancer in the U.S. in March 2021.

Moreover, companies are acquiring providers of the related solutions to enhance their presence. For instance, Laboratory Corporation of America Holdings announced plans to acquire the autoimmune business unit of Myriad Genetics in May 2021. Similarly, Quest Diagnostics signed an agreement with GRAIL in February 2021 for the former to supply collected specimens for testing via Galleri, a blood test kit for the early diagnosis of certain cancers.

Moreover, Europe will show significant growth in this market due to the advancement in the regional countries’ health infrastructure, rising incidence of communicable diseases, and favorable policies for reimbursement. The European Commission estimates that between 27 and 36 million persons in Europe are affected by uncommon diseases. Additionally, the Centers for Disease Control and Prevention estimates that there were about 54,285 salmonella cases in 2017.

In the continent, the adoption of esoteric testing methods is rising swiftly in Germany, due to an increase in the prevalence of degenerative diseases, expansion of screening practices, and technological developments in specialized screening methods. Moreover, with the growing awareness of precise tests for diseases among the population, as a result of the government-sponsored programs, healthcare personnel are adopting these solutions for accurate and early detection.

APAC is expected to progress with the highest CAGR during the forecast period. This is primarily due to the increasing awareness of esoteric tests, rising focus of companies on expanding their operations in countries such as India, Australia, and South Korea, and booming prevalence of chronic ailments.

Report Breakdown

Based on Test Type

• Infectious Diseases Testing
• Endocrinology Testing
• Oncology Testing
• Genetics Testing
• Toxicology Testing
• Immunology Testing
• Neurology Testing

Based on Technology

• Chemiluminescence Immunoassay
• Enzyme-Linked Immunosorbent Assay
• Mass Spectrometry
• Real-Time PCR
• DNA Sequencing
• Flow Cytometry

Based on End User

• Independent & Reference Laboratories
• Hospital-Based Laboratories

Geographical Analysis

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
• Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • U.A.E.

Top Esoteric Testing Solutions Providing Companies